Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on nitric oxide (NO) treatments, has scheduled its fiscal Q2 2025 financial results conference call for November 11, 2024, after market close. The earnings call will be held at 4:30 PM ET, accessible via phone (domestic: 1-877-407-0784; international: 1-201-689-8560) and webcast through the company's website. A replay will be available online after the call.
Beyond Air (NASDAQ: XAIR), un'azienda che opera nel settore dei dispositivi medici e della biopharma, focalizzata sui trattamenti a base di ossido nitrico (NO), ha programmato la sua conferenza sui risultati finanziari del secondo trimestre fiscale del 2025 per il 11 novembre 2024, dopo la chiusura del mercato. La chiamata sugli utili avrà luogo alle 16:30 ET, accessibile tramite telefono (nazionale: 1-877-407-0784; internazionale: 1-201-689-8560) e in diretta streaming attraverso il sito web dell'azienda. Una registrazione sarà disponibile online dopo la chiamata.
Beyond Air (NASDAQ: XAIR), una empresa de dispositivos médicos y biofarmacéutica en etapa comercial centrada en tratamientos con óxido nítrico (NO), ha programado su conferencia sobre resultados financieros del segundo trimestre fiscal de 2025 para el 11 de noviembre de 2024, después del cierre del mercado. La llamada sobre ganancias se llevará a cabo a las 4:30 PM ET, accesible por teléfono (nacional: 1-877-407-0784; internacional: 1-201-689-8560) y se transmitirá en vivo a través del sitio web de la empresa. Una repetición estará disponible en línea después de la llamada.
비욘드 에어 (NASDAQ: XAIR), 질산산화물(NO) 치료에 집중하는 상업 단계의 의료기기 및 생물의약품 회사는 2025 회계연도 2분기 재무 결과에 대한 컨퍼런스 콜을 2024년 11월 11일에, 시장 종료 후에 예정하고 있습니다. 수익 콜은 동부 표준시(ET) 기준으로 오후 4시 30분에 진행되며, 전화(국내: 1-877-407-0784; 국제: 1-201-689-8560)와 회사 웹사이트를 통해 웹캐스트로 접근할 수 있습니다. 콜 후에는 온라인으로 다시 청취할 수 있습니다.
Beyond Air (NASDAQ: XAIR), une entreprise de dispositifs médicaux et de biopharmaceutiques en phase commerciale axée sur les traitements à base d'oxyde nitrique (NO), a programmé sa conférence sur les résultats financiers du deuxième trimestre fiscal 2025 pour le 11 novembre 2024, après la fermeture du marché. L'appel de résultats se tiendra à 16h30 ET, accessible par téléphone (national : 1-877-407-0784 ; international : 1-201-689-8560) et en webdiffusion via le site web de l'entreprise. Un enregistrement sera disponible en ligne après l'appel.
Beyond Air (NASDAQ: XAIR), ein Unternehmen im kommerziellen Bereich für medizinische Geräte und Biopharmazeutika, das sich auf Behandlungen mit Stickstoffmonoxid (NO) konzentriert, hat die Konferenz zur Bekanntgabe der finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 für den 11. November 2024 nach Börsenschluss angesetzt. Der Earnings Call findet um 16:30 Uhr ET statt und ist telefonisch erreichbar (innerhalb der USA: 1-877-407-0784; international: 1-201-689-8560) sowie über einen Livestream auf der Unternehmenswebsite. Eine Aufzeichnung wird nach dem Call online verfügbar sein.
- None.
- None.
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes.
| Conference Call & Webcast | ||
| Monday, November 11th @ 4:30 PM ET | ||
| Domestic: | 1-877-407-0784 | |
| International: | 1-201-689-8560 | |
| Conference ID: | 13749670 | |
| Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call. | |
About Beyond Air®, Inc.
Beyond Air, Inc. (NASDAQ: XAIR) is a global leader in medical technology focused on developing transformative treatments for lung diseases. The company’s LungFit® platform is a revolutionary NO generation and delivery system aimed at treating a variety of respiratory conditions, from neonatal intensive care needs to adult respiratory distress. Beyond Air’s innovative, portable systems are designed to eliminate the need for NO storage and transportation, improving both patient safety and healthcare efficiency.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
FAQ
When will Beyond Air (XAIR) report its Q2 2025 earnings?
How can I access Beyond Air's (XAIR) Q2 2025 earnings call?
What is the conference ID for Beyond Air's (XAIR) Q2 2025 earnings call?
